US FDA pushes ahead with off-label rules
This article was originally published in Clinica
The FDA is pushing ahead with its plans to relax its policy surrounding the use of medical and scientific journal articles relating to off-label uses for medical devices and drugs.
You may also be interested in...
Australian patients with phototoxicity due to the rare condition EPP will now have their first treatment option – provided the drug's developer, Clinuvel, secures reimbursement under the Pharmaceutical Benefits Scheme.
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
Resilience has raised $800m to develop new technologies to manufacture complex drugs including vaccines, cell therapies and gene therapies.